...
search icon
pbyi-img

Puma Biotechnology Inc, Common Stock

PBYI

NSQ

$2.89

-$0.15

(-4.93%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$141.62M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
6.4681
Volume info-icon
This is the total number of shares traded during the most recent trading day.
445.01K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.23 L
$7.73 H
$2.89

About Puma Biotechnology Inc, Common Stock

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePBYISectorS&P500
1-Week Return-2.36%1.77%-0.48%
1-Month Return-5.25%6.76%3.25%
3-Month Return1.4%-6.43%
6-Month Return-19.39%-1.84%9.96%
1-Year Return-38.51%4.62%25.34%
3-Year Return17.48%11.92%34.47%
5-Year Return-63.23%48.14%88.14%
10-Year Return-98.59%110.84%200.56%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue272.30M225.10M253.20M228.00M235.64M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":82.67,"profit":true},{"date":"2021-12-31","value":92.99,"profit":true},{"date":"2022-12-31","value":83.73,"profit":true},{"date":"2023-12-31","value":86.54,"profit":true}]
Cost of Revenue36.80M39.40M63.70M55.10M62.68M[{"date":"2019-12-31","value":57.77,"profit":true},{"date":"2020-12-31","value":61.85,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.5,"profit":true},{"date":"2023-12-31","value":98.4,"profit":true}]
Gross Profit235.50M185.70M189.50M172.90M172.96M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":78.85,"profit":true},{"date":"2021-12-31","value":80.47,"profit":true},{"date":"2022-12-31","value":73.42,"profit":true},{"date":"2023-12-31","value":73.44,"profit":true}]
Gross Margin86.49%82.50%74.84%75.83%73.40%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.39,"profit":true},{"date":"2021-12-31","value":86.54,"profit":true},{"date":"2022-12-31","value":87.68,"profit":true},{"date":"2023-12-31","value":84.87,"profit":true}]
Operating Expenses274.60M216.10M188.20M142.20M140.31M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":78.7,"profit":true},{"date":"2021-12-31","value":68.54,"profit":true},{"date":"2022-12-31","value":51.78,"profit":true},{"date":"2023-12-31","value":51.1,"profit":true}]
Operating Income(39.10M)(30.40M)(8.90M)23.70M32.64M[{"date":"2019-12-31","value":-119.79,"profit":false},{"date":"2020-12-31","value":-93.14,"profit":false},{"date":"2021-12-31","value":-27.26,"profit":false},{"date":"2022-12-31","value":72.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(48.67M)(42.99M)(42.74M)(34.04M)(20.82M)[{"date":"2019-12-31","value":-4867200000,"profit":false},{"date":"2020-12-31","value":-4298600000,"profit":false},{"date":"2021-12-31","value":-4273900000,"profit":false},{"date":"2022-12-31","value":-3404200000,"profit":false},{"date":"2023-12-31","value":-2081600000,"profit":false}]
Pre-Tax Income(75.60M)(59.80M)(28.80M)500.00K22.67M[{"date":"2019-12-31","value":-333.42,"profit":false},{"date":"2020-12-31","value":-263.74,"profit":false},{"date":"2021-12-31","value":-127.02,"profit":false},{"date":"2022-12-31","value":2.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes7.12M200.00K300.00K500.00K1.08M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":2.81,"profit":true},{"date":"2021-12-31","value":4.21,"profit":true},{"date":"2022-12-31","value":7.02,"profit":true},{"date":"2023-12-31","value":15.2,"profit":true}]
Income After Taxes(82.72M)(60.00M)(29.10M)-21.59M[{"date":"2019-12-31","value":-383.14,"profit":false},{"date":"2020-12-31","value":-277.89,"profit":false},{"date":"2021-12-31","value":-134.78,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(75.59M)(59.99M)(29.13M)2.00K3.72M[{"date":"2019-12-31","value":-2033.76,"profit":false},{"date":"2020-12-31","value":-1614.07,"profit":false},{"date":"2021-12-31","value":-783.59,"profit":false},{"date":"2022-12-31","value":0.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(82.72M)(60.00M)(29.10M)912.00K21.59M[{"date":"2019-12-31","value":-383.14,"profit":false},{"date":"2020-12-31","value":-277.89,"profit":false},{"date":"2021-12-31","value":-134.78,"profit":false},{"date":"2022-12-31","value":4.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)(1.96)(1.52)(0.53)-0.46[{"date":"2019-12-31","value":-426.09,"profit":false},{"date":"2020-12-31","value":-330.43,"profit":false},{"date":"2021-12-31","value":-115.22,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PBYI
Cash Ratio 0.88
Current Ratio 1.42
Quick Ratio 1.40

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PBYI
ROA (LTM) 9.73%
ROE (LTM) 42.32%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PBYI
Debt Ratio Lower is generally better. Negative is bad. 0.68
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.32

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PBYI
Trailing PE 6.15
Forward PE 3.90
P/S (TTM) 0.58
P/B 2.00
Price/FCF 13
EV/R 0.54
EV/Ebitda 2.66
PEG 0.03

FAQs

What is Puma Biotechnology Inc share price today?

Puma Biotechnology Inc (PBYI) share price today is $2.89

Can Indians buy Puma Biotechnology Inc shares?

Yes, Indians can buy shares of Puma Biotechnology Inc (PBYI) on Vested. To buy Puma Biotechnology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PBYI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Puma Biotechnology Inc be purchased?

Yes, you can purchase fractional shares of Puma Biotechnology Inc (PBYI) via the Vested app. You can start investing in Puma Biotechnology Inc (PBYI) with a minimum investment of $1.

How to invest in Puma Biotechnology Inc shares from India?

You can invest in shares of Puma Biotechnology Inc (PBYI) via Vested in three simple steps:

  • Click on Sign Up or Invest in PBYI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Puma Biotechnology Inc shares
What is Puma Biotechnology Inc 52-week high and low stock price?

The 52-week high price of Puma Biotechnology Inc (PBYI) is $7.73. The 52-week low price of Puma Biotechnology Inc (PBYI) is $2.23.

What is Puma Biotechnology Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Puma Biotechnology Inc (PBYI) is 6.4681

What is Puma Biotechnology Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Puma Biotechnology Inc (PBYI) is 2.00

What is the Market Cap of Puma Biotechnology Inc?

The market capitalization of Puma Biotechnology Inc (PBYI) is $141.62M

What is Puma Biotechnology Inc’s stock symbol?

The stock symbol (or ticker) of Puma Biotechnology Inc is PBYI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top